Exelixis, Inc. (EXEL)
64.53
-0.78
(-1.19%)
USD |
NASDAQ |
Oct 23, 16:00
64.56
+0.03
(+0.05%)
Pre-Market: 20:00
Exelixis Enterprise Value : 15.39B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 15.39B |
| October 22, 2026 | 15.58B |
| October 21, 2026 | 15.40B |
| October 20, 2026 | 15.35B |
| October 19, 2026 | 14.93B |
| October 16, 2026 | 14.81B |
| October 15, 2026 | 14.96B |
| October 14, 2026 | 14.51B |
| October 13, 2026 | 14.14B |
| October 12, 2026 | 14.21B |
| October 09, 2026 | 14.22B |
| October 08, 2026 | 14.02B |
| October 07, 2026 | 13.87B |
| October 06, 2026 | 13.84B |
| October 05, 2026 | 13.97B |
| October 02, 2026 | 13.86B |
| October 01, 2026 | 13.75B |
| September 30, 2026 | 13.86B |
| September 29, 2026 | 13.92B |
| September 28, 2026 | 13.85B |
| September 25, 2026 | 13.80B |
| September 24, 2026 | 13.75B |
| September 23, 2026 | 13.45B |
| September 22, 2026 | 13.80B |
| September 21, 2026 | 13.57B |
| Date | Value |
|---|---|
| September 18, 2026 | 13.85B |
| September 17, 2026 | 13.88B |
| September 16, 2026 | 13.46B |
| September 15, 2026 | 13.49B |
| September 14, 2026 | 13.32B |
| September 11, 2026 | 13.29B |
| September 10, 2026 | 13.62B |
| September 09, 2026 | 13.84B |
| September 08, 2026 | 13.68B |
| September 04, 2026 | 14.01B |
| September 03, 2026 | 14.04B |
| September 02, 2026 | 13.89B |
| September 01, 2026 | 13.49B |
| August 31, 2026 | 12.93B |
| August 28, 2026 | 12.88B |
| August 27, 2026 | 13.08B |
| August 26, 2026 | 13.29B |
| August 25, 2026 | 13.44B |
| August 24, 2026 | 12.90B |
| August 21, 2026 | 12.79B |
| August 20, 2026 | 12.69B |
| August 19, 2026 | 12.86B |
| August 18, 2026 | 12.55B |
| August 17, 2026 | 12.35B |
| August 14, 2026 | 12.08B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| BioMarin Pharmaceutical, Inc. | 14.17B |
| Cytokinetics, Inc. | 8.598B |
| Emergent BioSolutions, Inc. | 766.90M |
| Gilead Sciences, Inc. | 214.93B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 212.05M |
| Revenue (Quarterly) | 628.69M |
| Total Expenses (Quarterly) | 416.64M |
| EPS Diluted (Quarterly) | 0.8166 |
| Gross Profit Margin (Quarterly) | 96.71% |
| Profit Margin (Quarterly) | 33.73% |
| Earnings Yield | 4.93% |
| Operating Earnings Yield | 5.68% |
| Normalized Earnings Yield | 5.014 |